Introduction: The scope of using no carrier added (NCA) ⁹⁰Y[T_1/2=64.1h,E_β(max)= 2.28 MeV] obtained from ⁹⁰Sr/⁹⁰Y generator in radiation synovectomy(RSV) is widely accepted. In the present study, the prospect of using ⁹⁰Y produced by (n,γ) route in a medium flux research reactor for use in RSV was explored. Methods: Yttrium-90 was produced by thermal neutron irradiation of Y₂O₃ target at a neutron flux of~1× 10¹⁴n/cm².s for 14 d. The influence of various experimental parameters were systematically investigated and optimized to arrive at the most favorable conditions for the formulation of ⁹⁰Y labelled hydroxyapatite (HA) using HA particles of 1–10μm size range. An optimized kit formulation strategy was developed for convenient one-step compounding of ⁹⁰Y-HA, which is easily adaptable at hospital radio pharmacy . The pre-clinical biological evaluation of ⁹⁰Y-HA particles was studied by carrying out bio distribution and bioluminiscence imaging studies in Wistar rats. The first clinical investigation using the radiolabeled preparation was performed on a patient suffering from chronic arthritis in knee joint by administering 185 MBq ⁹⁰Y-HA formulated at the hospital radiopharmacy deploying the proposed strategy. Results: Yttrium-90 was produced with a specific activity of 851 ± 111 MBq/mg and radionuclidic purity of 99.95 ±0.02%.⁹⁰Y-labeled HA particles (185 ± 10 MBq doses) were formulated in high radiochemical purity (>99%) and excellent in vitro stability. The preparation showed promising results in pre-clinical studies carried out in Wistar rats. The preliminary results of the first clinical investigation of ⁹⁰Y-HA preparation in a patient with rheumatoid arthritis in knee joints demonstrated the effectiveness of the formulation prepared using ⁹⁰Y produced via(n,γ) route in the management of the disease. Conclusion: The studies revealed that effective utilization of ⁹⁰Y produced via(n,γ) route in a medium flux research reactor coupled with the developed strategy of using HA kits for convenient formulation of ⁹⁰Y-HA at the hospital radiopharmacy can contribute to sustainable growth in the clinical utilization of ⁹⁰Y in RSV in the foreseeable future.